<DOC>
	<DOCNO>NCT00519376</DOCNO>
	<brief_summary>This study involve use new compound , GW642444 develop treatment asthma chronic obstructive pulmonary disease ( COPD ) . It work act cell lung , cause muscle around lung relax open good ( bronchodilation ) , make breathe easy . When medicine make form ready give patient , active ingredient often prepared form salt , inactive ingredient ( excipients ) often add . Inactive ingredient might use help medicine work well , make easy produce medicine , make easy get accurate dose medicine . In previous study study drug give dry powder form either ' H ' salt ( excipient lactose ) , form 'M ' salt ( excipients lactose cellobiose octaacetate ) . In study 'M ' salt form study drug prepare lactose new excipient call magnesium stearate ( instead cellobiose octaacetate ) . Participants study receive ' H ' salt ( GW642444H ) new 'M ' salt ( GW642444M ) contain magnesium stearate . This study first time new 'M ' salt form study drug give COPD patient .</brief_summary>
	<brief_title>A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion criterion : Male female ( nonchildbearing potential ) &gt; = 40 year History COPD Smoker exsmoker Body weight &gt; = 50 kg BMI 1832 kg/m2 Exclusion criterion : History significant disease Subjects primary asthma diagnosis Alpha1 antitrypsin deficiency underlie cause COPD Recent respiratory tract infection Poorly control COPD Blood potassium level &lt; 3.5mmol/L Shortterm long tern oxygen therapy Recent participation another trial History drug alcohol abuse Known allergy Recent blood donation ECG abnormality</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>pharmacodynamics ,</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>safety ,</keyword>
	<keyword>COPD patient</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>tolerability ,</keyword>
	<keyword>GW642444 ,</keyword>
</DOC>